The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • No CSPEC related information was provided by the message!

  • See Evidence submitted by expert panel for details.

Variant: NM_000018.4(ACADVL):c.1372T>C (p.Phe458Leu)

CA251907

1632 (ClinVar)

Gene: ACADVL
Condition: very long chain acyl-CoA dehydrogenase deficiency
Inheritance Mode: Autosomal recessive inheritance
UUID: 6123ebea-ce35-4138-b97c-868a048a9cfa
Approved on: 2022-12-14
Published on: 2022-12-14

HGVS expressions

NM_000018.4:c.1372T>C
NM_000018.4(ACADVL):c.1372T>C (p.Phe458Leu)
NC_000017.11:g.7224007T>C
CM000679.2:g.7224007T>C
NC_000017.10:g.7127326T>C
CM000679.1:g.7127326T>C
NC_000017.9:g.7068050T>C
NG_007975.1:g.9174T>C
NG_008391.2:g.1044A>G
NG_033038.1:g.15538A>G
ENST00000356839.10:c.1372T>C
ENST00000322910.9:c.*1327T>C
ENST00000350303.9:c.1306T>C
ENST00000356839.9:c.1372T>C
ENST00000542255.6:n.230T>C
ENST00000543245.6:c.1441T>C
ENST00000578711.1:n.503T>C
ENST00000579425.5:n.488T>C
ENST00000579546.1:n.209T>C
ENST00000579894.5:n.83T>C
ENST00000583074.5:n.91T>C
ENST00000583850.5:n.147T>C
ENST00000583858.5:n.401T>C
ENST00000585203.6:n.563T>C
NM_000018.3:c.1372T>C
NM_001033859.2:c.1306T>C
NM_001270447.1:c.1441T>C
NM_001270448.1:c.1144T>C
NM_001033859.3:c.1306T>C
NM_001270447.2:c.1441T>C
NM_001270448.2:c.1144T>C

Likely Pathogenic

Met criteria codes 5
PM2_Supporting PP4 PP3 PS3_Supporting PM3_Strong

Evidence Links 1

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
ACADVL VCEP
The c.1372T>C variant is a missense variant predicted to cause substitution of phenylalanine by leucine at amino acid 458 (p.Phe458Leu). This variant has also been published as Phe418Leu when numbered from the mature peptide. The c.1372T>C variant has been described in at least three individuals diagnosed with very long chain acyl CoA dehydrogenase (VLCAD), with at least two also carrying an additional pathogenic or likely pathogenic ACADVL variant confirmed in trans (PM3_Strong). At least one patient with this variant displayed VLCAD activity 20% of normal, which is highly specific for VLCAD deficiency (PP4; PMID: 9709714). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00001759 in European (non-Finnish) population, which is lower than the ClinGen ACADVL Variant Curation Expert Panel threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting). Recombinant protein expressing this variant showed reduced VLCAD enzyme activity, indicating that this variant impacts protein function (PS3_Supporting; PMID: 9461620). The computational predictor REVEL gives a score of 0.828, which is above the threshold of 0.75, evidence that correlates with impact to ACADVL function (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for autosomal recessive VLCAD deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen ACADVL Variant Curation Expert Panel: PM3_Strong, PP4, PM2_Supporting, PS3_Supporting, PP3 (ACADVL VCEP specifications version 1; approved November 8, 2021).
Met criteria codes
PM2_Supporting
The highest population minor allele frequency in gnomAD v2.1.1 is 0.00001759 in European (non-Finnish) population, which is lower than the ClinGen ACADVL Variant Curation Expert Panel threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting).
PP4
VLCAD 20% of normal in PMID 9709714
PP3
The computational predictor REVEL gives a score of 0.828, which is above the threshold of 0.75, evidence that correlates with impact to ACADVL function (PP3).
PS3_Supporting
Recombinant protein expressing this variant showed reduced VLCAD enzyme activity, indicating that this variant impacts protein function (PMID: 9461620) (PS3_Supporting).

PM3_Strong
Detected confirmed in trans to IVS8-2A>C (c.753-2A>C, approved pathogenic by VCEP) by parental testing. Confirmed in trans to c.1679-6G>A (proposed LP) by subcloning.
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.